오피오이드 사용 장애 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약물 유형별, 투여 경로별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Opioid Use Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1703340
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 183 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
오피오이드 사용 장애 치료제 세계 시장 규모는 2024년 38억 7,000만 달러로 평가되었고, 예측 기간 동안 65억 9,000만 달러, 2030년까지 9.26%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
오피오이드 사용 장애 치료제 세계 시장은 제약 산업에서 가장 역동적이고 중요한 부문으로, 전 세계적으로 심각해지고 있는 오피오이드 중독 위기에 대응하기 위해 노력하고 있습니다. 오피오이드 남용 및 과다복용과 관련된 사망자 수가 우려할 만한 수준에 이르렀기 때문에 이 시장은 이 공중보건 위기에 대처하기 위한 효과적인 솔루션을 제공하는 데 있어 매우 중요한 역할을 하고 있습니다. 오피오이드 사용 장애(OUD) 치료제에는 처방 진통제 및 헤로인과 같은 불법 약물을 포함한 오피오이드 중독을 치료하기 위해 고안된 다양한 의약품이 포함됩니다. 이러한 약물은 일반적으로 오피오이드 작용제, 부분 작용제, 길항제의 세 가지 범주로 나뉘며, 각각 고유한 작용기전을 가지고 있습니다. 이 시장의 주요 약물에는 메타돈, 부프레노르핀, 나트렉손, 나록손 등이 있으며, 경구용 정제, 설하 필름, 주사제 등 다양한 형태로 투여됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
38억 7,000만 달러
시장 규모 : 2030년
65억 9,000만 달러
CAGR : 2025-2030년
9.26%
급성장 부문
온라인 약국
최대 시장
북미
시장 성장 촉진요인
오피오이드 확산의 심각성
주요 시장 이슈
규제의 복잡성
주요 시장 동향
약물 보조 치료(MAT) 확대
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 오피오이드 사용 장애 치료제 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
약제 유형별(Agonist Drugs, Antagonist Drugs, 기타)
투여 경로(경구, 비경구, 설하, 경비)
유통 채널별(병원 약국, 소매 약국, 온라인 약국)
기업별(2024년)
지역별
시장 맵
제6장 북미의 오피오이드 사용 장애 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제7장 유럽의 오피오이드 사용 장애 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 오피오이드 사용 장애 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
한국
일본
호주
제9장 남미의 오피오이드 사용 장애 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 오피오이드 사용 장애 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
제품 출시
인수합병(M&A)
제13장 PESTEL 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Mallinckrodt Pharmaceuticals
Hikma Pharmaceuticals Inc
Collegium Pharmaceutical, Inc.
Braeburn, Inc.
Purdue Pharma L.P.
Curia Global Inc.
EMERGENT
Bristol-Myers Squibb, S.r.l
Alkermes, Inc.
Indivior Inc.
제16장 전략적 제안
제17장 리서치사에 대해 & 면책사항
LSH
영문 목차
영문목차
Global Opioid Use Disorder Drugs Market was valued at USD 3.87 Billion in 2024 and is expected to reach USD 6.59 Billion in the forecast period with a CAGR of 9.26% through 2030. The Global Opioid Use Disorder Drugs Market is a dynamic and critical segment within the broader pharmaceutical industry, dedicated to addressing the escalating crisis of opioid addiction worldwide. With opioid abuse and overdose-related deaths reaching alarming levels, this market plays a pivotal role in providing effective solutions to combat this public health crisis. Opioid Use Disorder (OUD) drugs encompass a range of pharmaceutical interventions designed to treat addiction to opioids, including prescription painkillers and illicit substances like heroin. These medications typically fall into three categories: opioid agonists, partial agonists, and antagonists, each with its unique mechanism of action. Key drugs within this market include methadone, buprenorphine, naltrexone, and naloxone, which are administered in various forms such as oral tablets, sublingual films, or injectables.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 3.87 Billion
Market Size 2030
USD 6.59 Billion
CAGR 2025-2030
9.26%
Fastest Growing Segment
Online Pharmacies
Largest Market
North America
Key Market Drivers
Escalating Opioid Epidemic
The escalating opioid epidemic has significantly influenced the Global Opioid Use Disorder (OUD) Drugs Market, reshaping the pharmaceutical landscape in response to this pressing public health crisis. This crisis, marked by the widespread misuse of prescription opioids and the proliferation of illicit substances like heroin, has led to devastating consequences, including a substantial number of opioid-related deaths. According to provisional data from the Centers for Disease Control and Prevention (CDC), there were an estimated 107,543 drug overdose deaths in the United States during 2023, with approximately 81,083 involving opioids. As communities confront the severe impacts of addiction, the demand for effective treatments has surged, creating opportunities for pharmaceutical companies to develop, market, and distribute a range of OUD drugs.
The opioid epidemic has unfolded on a global scale, transcending geographical and demographic boundaries. Governments, healthcare organizations, and the public have recognized the urgency of addressing this crisis comprehensively. This collective awareness has spurred significant investments in addiction treatment programs and policies aimed at expanding access to OUD drugs. However, challenges remain. In 2021, an estimated 2.5 million people aged 18 years or older in the U.S. had opioid use disorder, yet only 22% received medications to treat it. Addressing such gaps is crucial for mitigating the epidemic's impact. Furthermore, advancements like extended-release formulations have made treatment more convenient for patients, contributing to improved adherence and outcomes. As healthcare professionals and policymakers continue to grapple with the opioid crisis, the pharmaceutical industry remains pivotal in developing innovative medications to effectively treat OUD.
Key Market Challenges
Regulatory Complexity
One of the primary challenges is the lack of uniformity in regulations across different regions and countries. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and counterparts in other nations, have unique guidelines and requirements for OUD medications. This variation can lead to confusion and increased compliance costs for pharmaceutical companies operating internationally. The opioid epidemic is a rapidly evolving crisis, and regulatory agencies often struggle to keep pace with emerging trends and challenges. This lag in adapting regulations can hinder the timely approval of new medications and treatment modalities, impeding the market's ability to respond effectively to the crisis.
OUD medications, including opioid agonists like methadone and buprenorphine, are subject to strict regulations surrounding their prescription and dispensing. Healthcare providers must undergo specialized training and obtain waivers to prescribe these medications, creating barriers to access. Furthermore, stringent record-keeping requirements and oversight can deter providers from offering these treatments. Some OUD medications are subject to Risk Evaluation and Mitigation Strategies, which impose additional requirements on manufacturers and healthcare providers. While these strategies are intended to enhance the safe use of medications, they can also increase the administrative burden and costs associated with bringing OUD drugs to market.
Key Market Trends
Expansion of Medication-Assisted Treatment (MAT)
One of the most significant trends in the OUD Drugs Market is the increasing adoption of Medication-Assisted Treatment (MAT). MAT combines pharmacotherapy, such as opioid agonists (e.g., methadone and buprenorphine), with counseling and behavioral therapies to address opioid addiction comprehensively. MAT is now widely recognized as the gold standard of care for OUD, and its expansion has significantly boosted the market. Increased Access to Treatment: MAT programs have proliferated, making treatment more accessible to individuals grappling with OUD. The availability of MAT in a variety of healthcare settings, including specialized clinics, primary care offices, and even pharmacies, has broadened the reach of OUD treatment. MAT has demonstrated its effectiveness in reducing opioid misuse, promoting long-term recovery, and preventing opioid overdose deaths. As more individuals have access to MAT, better treatment outcomes become achievable, leading to increased confidence in these therapies.
Key Market Players
Mallinckrodt Pharmaceuticals
Hikma Pharmaceuticals Inc
Collegium Pharmaceutical, Inc.
Braeburn, Inc.
Purdue Pharma L.P.
Curia Global Inc.
EMERGENT
Bristol-Myers Squibb, S.r.l
Alkermes, Inc.
Indivior Inc.
Report Scope:
In this report, the Global Opioid Use Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Opioid Use Disorder Drugs Market, By Drug Type:
Agonist Drugs
Antagonist Drugs
Others
Opioid Use Disorder Drugs Market, By Route of Administration:
Oral
Parenteral
Sublingual
Nasal
Opioid Use Disorder Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Opioid Use Disorder Drugs Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Opioid Use Disorder Drugs Market.
Available Customizations:
Global Opioid Use Disorder Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Opioid Use Disorder Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type (Agonist Drugs, Antagonist Drugs, Others)
5.2.2. By Route of Administration (Oral, Parenteral, Sublingual, Nasal)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.4. By Company (2024)
5.2.5. By Region
5.3. Market Map
6. North America Opioid Use Disorder Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Opioid Use Disorder Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Mexico Opioid Use Disorder Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Canada Opioid Use Disorder Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. Europe Opioid Use Disorder Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Opioid Use Disorder Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. Germany Opioid Use Disorder Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Opioid Use Disorder Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Opioid Use Disorder Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Opioid Use Disorder Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Opioid Use Disorder Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Opioid Use Disorder Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Opioid Use Disorder Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. South Korea Opioid Use Disorder Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. Japan Opioid Use Disorder Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Opioid Use Disorder Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. South America Opioid Use Disorder Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Opioid Use Disorder Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina Opioid Use Disorder Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia Opioid Use Disorder Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Opioid Use Disorder Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Opioid Use Disorder Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia Opioid Use Disorder Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. UAE Opioid Use Disorder Drugs Market Outlook
